Oncology Commitment

At AbbVie, we are committed to tackling the toughest challenges in oncology. Our team of oncology experts is working to transform the way cancer is treated and to develop and deliver breakthroughs for patients.   

Blood Cancers

AbbVie is committed to the study of hematologic diseases, driving innovation in chronic lymphocytic leukemia, acute myeloid leukemia, multiple myeloma and other blood cancers.

Solid Tumors

AbbVie is leveraging our expertise in blood cancer for novel research in some of the most difficult-to-treat solid tumors.

Oncology Collaborations

AbbVie is tackling the most difficult challenges in oncology through research and strategic collaborations that drive transformational improvements in cancer treatment and improve patient outcomes. We are proud to work with our partners, including the select list below, to make a remarkable impact on the lives of people affected by cancer around the world.

International Myeloma Foundation

Charting the role of genetic mutations through real-world evidence

AbbVie and the International Myeloma Foundation (IMF) are collaborating on a landmark retrospective chart review study to better understand and manage multiple myeloma (MM), the second-most common blood cancer. [1] Results of the study will provide insight into the relatively unknown role of the t(11;14) translocation genetic mutation in response to treatment, with the potential to advance care for patients
with MM.

[1] Kazandjian D. Multiple myeloma epidemiology and survival:
A unique malignancy. Semin Oncol. 2016;43:676-681.